Expert Interview
A second look at how payers within the U.S. are strategizing the reimbursement of Alzheimer's drugs such as Aducanumab (Aduhelm) and Lecanemab (Leqembi).
Ticker(s): BIIBInstitution: Script Care
- Director of pharmacy and medical affairs.
- Responsible for formulary management, development, and oversight. Leadership role at Pharmacy and Therapeutics committee.
- Responsible for utilization management, clinical protocols and pathways, plan development and design, emphasis on specialty pharmacy, diseases, and distribution channels, case management, digital therapeutics medical devices, NGS tests, HTA, Director over specialty pharmacy and ID system (payer is vertically integrated), oncology and infusion centers, and regulatory aspects across all sectors (commercial, Medicare, Medicaid, Hospital, pharmacy). Reimbursement and contracting strategies, GPOs, and other related areas.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
